Oncology Central

Immunotherapy may be an effective therapy for prostate cancer with mismatch repair mutations

A team of scientists at the Institute of Cancer Research (London, UK) and the Dana-Farber Cancer Institute (MA, US) have discovered that prostate cancer patients with DNA mismatch repair (MMR) gene mutations within their tumors suffer from particularly aggressive disease and were found to survive only half the length of time as men with tumors not containing MMR mutations.
Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.




News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.